Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

IBD metabonomics predicts phenotype, disease course, and treatment response

Research output: Contribution to journalReviewResearchpeer-review

  1. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. On the investigation of non-specific effects of BCG: Interpreting global vaccine data

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lipidomics and the quest for brainy lipids

    Research output: Contribution to journalComment/debateResearchpeer-review

  1. Reply

    Research output: Contribution to journalLetterResearchpeer-review

  2. Praktisk anvendelse af thiopuriner hos patienter med kronisk inflammatoriske tarmsygdomme

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Metabonomics in inflammatory bowel disease (IBD) characterizes the effector molecules of biological systems and thus aims to describe the molecular phenotype, generate insight into the pathology, and predict disease course and response to treatment. Nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and integrated NMR and MS platforms coupled with multivariate analyses have been applied to create such metabolic profiles. Recent advances have identified quiescent ulcerative colitis as a distinct molecular phenotype and demonstrated metabonomics as a promising clinical tool for predicting relapse and response to treatment with biologics as well as fecal microbiome transplantation, thus facilitating much needed precision medicine. However, understanding this complex research field and how it translates into clinical settings is a challenge. This review aims to describe the current workflow, analytical strategies, and associated bioinformatics, and translate current IBD metabonomic knowledge into new potential clinically applicable treatment strategies, and outline future key translational perspectives.

Original languageEnglish
Article number103551
Pages (from-to)103551
Publication statusPublished - Sep 2021

Bibliographical note

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

ID: 69747797